Difference between revisions of "Part:BBa K1699001:Design"

(→‎Design Notes)
(→‎Design Notes)
 
(5 intermediate revisions by 2 users not shown)
Line 6: Line 6:
  
 
===Design Notes===
 
===Design Notes===
 +
 +
Designed using Benchling to meet registry standards. Synthesized by Syntezza Biosience. Cloned into pSB1C3 using EcoRI and PstI restriction sites.
  
 
===Source===
 
===Source===
−
DNA Synthesis by Synthezza Bioscience. Cloning into iGEM vector was done by iGEM BGU 2015.
+
Human genomic DNA sequence.
−
 
+
Based on:
−
===References===
+
Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
−
 
+
Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B.
−
1. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters
+
Cancer Res. 2000 Oct 1;60(19):5359-64.
−
http://www.nature.com/gt/journal/v8/n7/pdf/3301421a.pdf
+
http://www.ncbi.nlm.nih.gov/pubmed/11034071

Latest revision as of 11:36, 13 September 2015

Human short TERT promoter


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

Designed using Benchling to meet registry standards. Synthesized by Syntezza Biosience. Cloned into pSB1C3 using EcoRI and PstI restriction sites.

Source

Human genomic DNA sequence. Based on: Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B. Cancer Res. 2000 Oct 1;60(19):5359-64. http://www.ncbi.nlm.nih.gov/pubmed/11034071